Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Seminars in Cancer Biology|July 6, 2020
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancerNicola Gaynor, John Crown, Denis M CollinsCancers|March 23, 2019
Acquired Resistance to Antibody-Drug ConjugatesDenis M Collins, Birgit Bossenmaier, Gwendlyn Kollmorgen, et al.Cancers|February 12, 2021
Research Strategies for Low-Survival CancersCaroline Conway, Denis M Collins, Amanda McCann, et al.Cancers|August 10, 2019
Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual ConferenceSara Charmsaz, Denis M Collins, Antoinette S Perry, et al.International Journal of Molecular Sciences|January 25, 2025
Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast CancerAmira F Mahdi, Niall Ashfield, John Crown, et al.Cancers|June 21, 2018
Innovative Technologies Changing Cancer TreatmentSara Charmsaz, Maria Prencipe, Maeve Kiely, et al.Investigational New Drugs|July 8, 2010
Modulation of P-gp expression by lapatinibGráinne Dunne, Laura Breen, Denis M Collins, et al.Cancers|May 31, 2019
Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast CancerDenis M Collins, Neil T Conlon, Srinivasaraghavan Kannan, et al.Cancer Chemotherapy and Pharmacology|January 16, 2024
Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cellsThamir M Mahgoub, Emmet J Jordan, Amira F Mahdi, et al.Cellular Immunology|July 25, 2017
Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell linesDenis M Collins, Kathy Gately, Clare Hughes, et al.Pageof 3